SERIES B-2 COMMON STOCK PURCHASE WARRANT Hepion Pharmaceuticals, Inc.Hepion Pharmaceuticals, Inc. • February 16th, 2024 • Pharmaceutical preparations
THIS SERIES B-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the eighteen (18) month anniversary of the Initial Exercise Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to 735,295 shares of common stock, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
HEPION PHARMACEUTICALS, INC. Edison, NJ 08837Hepion Pharmaceuticals, Inc. • February 16th, 2024 • Pharmaceutical preparations
HEPION PHARMACEUTICALS, INC. (the “Company”) is pleased to offer (this “Offer”) to you (“Holder”, “you” or similar terminology) the opportunity to receive new common stock purchase warrants (the “New Warrants”) to purchase up an aggregate of 1,470,590 shares (collectively, the “New Warrant Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), equal to 150% of the 980,393 shares of Common Stock (such shares, collectively, the “Warrant Shares”) issuable pursuant to the exercise of that certain Series B Common Stock Purchase Warrant, currently held by you and issued to you on October 3, 2023 (the “Existing Warrant”), as more particularly set forth on the signature page hereto, in consideration for exercising for cash all of the Existing Warrant (which currently has an exercise price per share of $4.85) at an exercise price per share of $2.10 (with such exercise price being established for purposes of compliance with Nasdaq Stock Market listing rules)
CONFIDENTIAL February 15, 2024Hepion Pharmaceuticals, Inc. • February 16th, 2024 • Pharmaceutical preparations • New York
The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by Hepion Pharmaceuticals, Inc. (the “Company”) to render Financial Services (as defined below) to the Company.
AMENDMENT NO. 1 TO SERIES A COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • February 16th, 2024 • Hepion Pharmaceuticals, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO SERIES A COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of February [ ], 2024, by and between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Holder”).
